Neuroprotective properties of 17β‐estradiol, progesterone, and raloxifene in MPTP C57Bl/6 mice
Identifieur interne : 000288 ( France/Analysis ); précédent : 000287; suivant : 000289Neuroprotective properties of 17β‐estradiol, progesterone, and raloxifene in MPTP C57Bl/6 mice
Auteurs : Sophie Callier [Canada, France] ; Marc Morissette [Canada] ; Michelle Grandbois [Canada] ; Didier Pélaprat [France] ; Thérèse Di Paolo [Canada]Source :
- Synapse [ 0887-4476 ] ; 2001-08.
English descriptors
Abstract
Previous work from our laboratory showed prevention of 1‐methyl‐4‐phenyl‐1,2,3,6 tetrahydropyridine (MPTP) induced dopamine depletion in striatum of C57Bl/6 mice by 17β‐estradiol, progesterone, and raloxifene, whereas 17α‐estradiol had no effect. The present study investigated the mechanism by which these compounds exert their neuroprotective activity. The hormonal effect on the dopamine transporter (DAT) was examined to probe the integrity of dopamine neurons and glutamate receptors in order to find a possible excitotoxic mechanism. Drugs were injected daily for 5 days before MPTP (four injections, 15 mg/kg ip at 2‐h intervals) and drug treatment continued for 5 more days. MPTP induced a decrease of striatal DAT‐specific binding (50% of control) and DAT mRNA in the substantia nigra (20% of control), suggesting that loss of neuronal nerve terminals was more extensive than cell bodies. This MPTP‐induced decrease of striatal [125I]RTI‐121 specific binding was prevented by 17β‐estradiol (2 μg/day), progesterone (2 μg/day), or raloxifene (5 mg/kg/day) but not by 17α‐estradiol (2 μg/day) or raloxifene (1 mg/kg/day). No treatment completely reversed the decreased levels of DAT mRNA in the substantia nigra. Striatal [125I]RTI‐121 specific binding was positively correlated with dopamine concentrations in intact, saline, or hormone‐treated MPTP mice. Striatal NMDA‐sensitive [3H]glutamate or [3H]AMPA specific binding remained unchanged in intact, saline, or hormone‐treated MPTP mice, suggesting the unlikely implication of changes of glutamate receptors in an excitotoxic mechanism. These results show a stereospecific neuroprotection by 17β‐estradiol of MPTP neurotoxicity, which is also observed with progesterone or raloxifene treatment. The present paradigm modeled early DA nerve cell damage and was responsive to hormones. Synapse 41:131–138, 2001. © 2001 Wiley‐Liss, Inc.
Url:
DOI: 10.1002/syn.1067
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 001059
- to stream Istex, to step Curation: 001059
- to stream Istex, to step Checkpoint: 001023
- to stream Main, to step Merge: 003676
- to stream Main, to step Curation: 003195
- to stream Main, to step Exploration: 003195
- to stream France, to step Extraction: 000288
Links to Exploration step
ISTEX:B0719D083E857A0A3FA74D0E91001342C596B93DLe document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Neuroprotective properties of 17β‐estradiol, progesterone, and raloxifene in MPTP C57Bl/6 mice</title><author><name sortKey="Callier, Sophie" sort="Callier, Sophie" uniqKey="Callier S" first="Sophie" last="Callier">Sophie Callier</name></author><author><name sortKey="Morissette, Marc" sort="Morissette, Marc" uniqKey="Morissette M" first="Marc" last="Morissette">Marc Morissette</name></author><author><name sortKey="Grandbois, Michelle" sort="Grandbois, Michelle" uniqKey="Grandbois M" first="Michelle" last="Grandbois">Michelle Grandbois</name></author><author><name sortKey="Pelaprat, Didier" sort="Pelaprat, Didier" uniqKey="Pelaprat D" first="Didier" last="Pélaprat">Didier Pélaprat</name></author><author><name sortKey="Di Paolo, Therese" sort="Di Paolo, Therese" uniqKey="Di Paolo T" first="Thérèse" last="Di Paolo">Thérèse Di Paolo</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:B0719D083E857A0A3FA74D0E91001342C596B93D</idno><date when="2001" year="2001">2001</date><idno type="doi">10.1002/syn.1067</idno><idno type="url">https://api-v5.istex.fr/document/B0719D083E857A0A3FA74D0E91001342C596B93D/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">001059</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">001059</idno><idno type="wicri:Area/Istex/Curation">001059</idno><idno type="wicri:Area/Istex/Checkpoint">001023</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">001023</idno><idno type="wicri:doubleKey">0887-4476:2001:Callier S:neuroprotective:properties:of</idno><idno type="wicri:Area/Main/Merge">003676</idno><idno type="wicri:Area/Main/Curation">003195</idno><idno type="wicri:Area/Main/Exploration">003195</idno><idno type="wicri:Area/France/Extraction">000288</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Neuroprotective properties of 17β‐estradiol, progesterone, and raloxifene in MPTP C57Bl/6 mice</title><author><name sortKey="Callier, Sophie" sort="Callier, Sophie" uniqKey="Callier S" first="Sophie" last="Callier">Sophie Callier</name><affiliation wicri:level="1"><country xml:lang="fr">Canada</country><wicri:regionArea>Oncology and Molecular Endocrinology Research Center, and Faculty of Pharmacy, Laval University, Québec, Qc, G1K 7P4</wicri:regionArea><wicri:noRegion>G1K 7P4</wicri:noRegion></affiliation><affiliation wicri:level="3"><country xml:lang="fr">France</country><wicri:regionArea>INSERM Unit 339, St.‐Antoine Hospital, 75012 Paris</wicri:regionArea><placeName><region type="region" nuts="2">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author><author><name sortKey="Morissette, Marc" sort="Morissette, Marc" uniqKey="Morissette M" first="Marc" last="Morissette">Marc Morissette</name><affiliation wicri:level="1"><country xml:lang="fr">Canada</country><wicri:regionArea>Oncology and Molecular Endocrinology Research Center, and Faculty of Pharmacy, Laval University, Québec, Qc, G1K 7P4</wicri:regionArea><wicri:noRegion>G1K 7P4</wicri:noRegion></affiliation></author><author><name sortKey="Grandbois, Michelle" sort="Grandbois, Michelle" uniqKey="Grandbois M" first="Michelle" last="Grandbois">Michelle Grandbois</name><affiliation wicri:level="1"><country xml:lang="fr">Canada</country><wicri:regionArea>Oncology and Molecular Endocrinology Research Center, and Faculty of Pharmacy, Laval University, Québec, Qc, G1K 7P4</wicri:regionArea><wicri:noRegion>G1K 7P4</wicri:noRegion></affiliation></author><author><name sortKey="Pelaprat, Didier" sort="Pelaprat, Didier" uniqKey="Pelaprat D" first="Didier" last="Pélaprat">Didier Pélaprat</name><affiliation wicri:level="3"><country xml:lang="fr">France</country><wicri:regionArea>INSERM Unit 339, St.‐Antoine Hospital, 75012 Paris</wicri:regionArea><placeName><region type="region" nuts="2">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author><author><name sortKey="Di Paolo, Therese" sort="Di Paolo, Therese" uniqKey="Di Paolo T" first="Thérèse" last="Di Paolo">Thérèse Di Paolo</name><affiliation wicri:level="1"><country xml:lang="fr">Canada</country><wicri:regionArea>Oncology and Molecular Endocrinology Research Center, and Faculty of Pharmacy, Laval University, Québec, Qc, G1K 7P4</wicri:regionArea><wicri:noRegion>G1K 7P4</wicri:noRegion></affiliation><affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Synapse</title><title level="j" type="abbrev">Synapse</title><idno type="ISSN">0887-4476</idno><idno type="eISSN">1098-2396</idno><imprint><publisher>John Wiley & Sons, Inc.</publisher><pubPlace>New York</pubPlace><date type="published" when="2001-08">2001-08</date><biblScope unit="volume">41</biblScope><biblScope unit="issue">2</biblScope><biblScope unit="page" from="131">131</biblScope><biblScope unit="page" to="138">138</biblScope></imprint><idno type="ISSN">0887-4476</idno></series><idno type="istex">B0719D083E857A0A3FA74D0E91001342C596B93D</idno><idno type="DOI">10.1002/syn.1067</idno><idno type="ArticleID">SYN1067</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0887-4476</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>dopamine transporter</term><term>glutamate</term><term>selective estrogen receptor modulator</term><term>steroid</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Previous work from our laboratory showed prevention of 1‐methyl‐4‐phenyl‐1,2,3,6 tetrahydropyridine (MPTP) induced dopamine depletion in striatum of C57Bl/6 mice by 17β‐estradiol, progesterone, and raloxifene, whereas 17α‐estradiol had no effect. The present study investigated the mechanism by which these compounds exert their neuroprotective activity. The hormonal effect on the dopamine transporter (DAT) was examined to probe the integrity of dopamine neurons and glutamate receptors in order to find a possible excitotoxic mechanism. Drugs were injected daily for 5 days before MPTP (four injections, 15 mg/kg ip at 2‐h intervals) and drug treatment continued for 5 more days. MPTP induced a decrease of striatal DAT‐specific binding (50% of control) and DAT mRNA in the substantia nigra (20% of control), suggesting that loss of neuronal nerve terminals was more extensive than cell bodies. This MPTP‐induced decrease of striatal [125I]RTI‐121 specific binding was prevented by 17β‐estradiol (2 μg/day), progesterone (2 μg/day), or raloxifene (5 mg/kg/day) but not by 17α‐estradiol (2 μg/day) or raloxifene (1 mg/kg/day). No treatment completely reversed the decreased levels of DAT mRNA in the substantia nigra. Striatal [125I]RTI‐121 specific binding was positively correlated with dopamine concentrations in intact, saline, or hormone‐treated MPTP mice. Striatal NMDA‐sensitive [3H]glutamate or [3H]AMPA specific binding remained unchanged in intact, saline, or hormone‐treated MPTP mice, suggesting the unlikely implication of changes of glutamate receptors in an excitotoxic mechanism. These results show a stereospecific neuroprotection by 17β‐estradiol of MPTP neurotoxicity, which is also observed with progesterone or raloxifene treatment. The present paradigm modeled early DA nerve cell damage and was responsive to hormones. Synapse 41:131–138, 2001. © 2001 Wiley‐Liss, Inc.</div></front></TEI><affiliations><list><country><li>Canada</li><li>France</li></country><region><li>Île-de-France</li></region><settlement><li>Paris</li></settlement></list><tree><country name="Canada"><noRegion><name sortKey="Callier, Sophie" sort="Callier, Sophie" uniqKey="Callier S" first="Sophie" last="Callier">Sophie Callier</name></noRegion><name sortKey="Di Paolo, Therese" sort="Di Paolo, Therese" uniqKey="Di Paolo T" first="Thérèse" last="Di Paolo">Thérèse Di Paolo</name><name sortKey="Grandbois, Michelle" sort="Grandbois, Michelle" uniqKey="Grandbois M" first="Michelle" last="Grandbois">Michelle Grandbois</name><name sortKey="Morissette, Marc" sort="Morissette, Marc" uniqKey="Morissette M" first="Marc" last="Morissette">Marc Morissette</name></country><country name="France"><region name="Île-de-France"><name sortKey="Callier, Sophie" sort="Callier, Sophie" uniqKey="Callier S" first="Sophie" last="Callier">Sophie Callier</name></region><name sortKey="Pelaprat, Didier" sort="Pelaprat, Didier" uniqKey="Pelaprat D" first="Didier" last="Pélaprat">Didier Pélaprat</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/France/Analysis
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000288 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/France/Analysis/biblio.hfd -nk 000288 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Canada
|area= ParkinsonCanadaV1
|flux= France
|étape= Analysis
|type= RBID
|clé= ISTEX:B0719D083E857A0A3FA74D0E91001342C596B93D
|texte= Neuroprotective properties of 17β‐estradiol, progesterone, and raloxifene in MPTP C57Bl/6 mice
}}
| This area was generated with Dilib version V0.6.29. |  |